Takeda announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase III clinical trial evaluating HYQVIA® for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropath, met its primary endpoint.
[Takeda]